Home › Research › TREM2 and immune genetics
CD33 in Alzheimer's Disease - Biology, Pathogenesis, and Therapeutics: A Mini-Review
Zhao L.. Gerontology, 2018-12-12
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease (AD) affects nearly 50 million people worldwide, and currently no disease-modifying treatment is available. With continuous failure of anti-amyloid-beta- or tau-based therapies, identification of new targets has become an urgent necessity for AD prevention and therapy. Recently, conventional genetic approaches and computational strategies have converged on immune-inflammatory pathways as key events in the pathogenesis of AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Zhao, L. (2019). CD33 in Alzheimer's Disease - Biology, Pathogenesis, and Therapeutics: A Mini-Review. Gerontology. https://doi.org/10.1159/000492596
Vancouver
Zhao L. CD33 in Alzheimer's Disease - Biology, Pathogenesis, and Therapeutics: A Mini-Review. Gerontology. 2019. doi:10.1159/000492596. PMID: 30541012.
BibTeX
@article{zhao2019-30541012,
author = {Zhao, L.},
title = {{CD33 in Alzheimer's Disease - Biology, Pathogenesis, and Therapeutics: A Mini-Review}},
journal = {Gerontology},
year = {2019},
doi = {10.1159/000492596},
pmid = {30541012},
url = {https://doi.org/10.1159/000492596}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- With continuous failure of anti-amyloid-beta- or tau-based therapies, identification of new targets has become an urgent necessity for AD prevention and therapy.
- Recently, conventional genetic approaches and computational strategies have converged on immune-inflammatory pathways as key events in the pathogenesis of AD.
- A number of genes have been highly linked to the onset and development of late-onset sporadic AD, the most common form of AD.
- Strikingly, most of these genes are involved in microglial biology.
Why it matters
This review discusses CD33 and immune-inflammatory pathways as possible targets in Alzheimer's disease and notes that no disease-modifying treatment is currently available. It is a summary of biology and target ideas, not evidence that any treatment, cure, or prevention works.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Gerontology) |
| Journal's citation record | 2 / 4 | Gerontology: journal h-index 151 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 122 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 13.6 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 2 / 6 | Cited 1.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 3 / 4 | Cited 52 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Lingzhi Zhao: h-index 12 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Cornell University: institution h-index 1,649 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30541012) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in TREM2 and immune genetics from nearby years
Also in TREM2 and immune genetics
86 studies in the library are filed under TREM2 and immune genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The TREM2 and immune genetics hub.